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Abstract
Background: Aseptic meningitis is a serious adverse reaction to intravenous immunoglobulin (IVIG) therapy. We
studied the clinical characteristics of patients with acute Kawasaki disease (KD) who developed IVIG-induced aseptic
meningitis.
Methods: A retrospective analysis of the medical records of patients with KD who developed aseptic meningitis
after IVIG treatment was performed.
Results: During the 10-year period from 2000 through 2009, among a total of 384 patients with Kawasaki disease,
4 (3 females and 1 male; age range, 19-120 months) developed aseptic meningitis after IVIG. All 4 developed
aseptic meningitis within 48 hours (range, 25-40 hours) of initiation of IVIG. The analyses of cerebrospinal fluid (CSF)
revealed elevated white blood cell counts (22-1,248/μL) in all 4 patients; a predominance of polynuclear cells (65%-
89%) was noted in 3. The CSF protein level was elevated in only 1 patient (59 mg/dL), and the glucose levels were
normal in all 4 patients. Two patients were treated with intravenous methylprednisolone; the other 2 children were
observed carefully without any special therapy. All patients recovered without neurological complications.
Conclusions: In our patients with Kawasaki disease, aseptic meningitis induced by IVIG occurred within 48 hours
after initiation of IVIG, resolved within a few days, and resulted in no neurological complications, even in patients
who did not receive medical treatment.
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Background
Intravenous immunoglobulin (IVIG) is a blood product
that is widely used in the treatment of a number of medi-
cal conditions, including immunodeficiency disorders,
inflammatory diseases, and autoimmune diseases.
Kawasaki disease (KD) is a self-limited systemic vascu-
litis syndrome of childhood that was first reported by
Tomisaku Kawasaki in 1967 [1]. Patients typically
develop a fever, bulbar conjunctival injection, changes in
the oropharyngeal mucosa and peripheral extremities,
cervical lymphadenopathy, and a polymorphous rash.
Coronary aneurysm and myocardial infarction are the
most serious complications of this disease. In Japan,
there are approximately 10,000 incident cases per year
[2]. The etiology of the disease is not well understood,
but high-dose IVIG is known to prevent the coronary
complications [3,4].
There have been a number of reports regarding IVIG-
induced adverse reactions, including mild reactions such
as tachycardia, headache, facial flushing, nausea, diarrhea,
and rash, as well as serious adverse reactions such as ana-
phylaxis, acute renal failure, and thromboembolic events
[5]. Aseptic meningitis is a neurologic adverse event that
can be caused by IVIG. Although there have been case
reports describing IVIG-induced aseptic meningitis, few
studies have described the characteristics of a group of
such patients. In this study, we describe the clinical and
laboratory characteristics of IVIG-induced aseptic menin-
gitis in 4 patients with KD.
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Patients
To investigate the clinical characteristics of IVIG-induced
meningitis in KD patients, we retrospectively reviewed
the medical records of patients who were admitted to our
university hospital during the 10-year period from 2000
through 2009. All patients met the Japanese criteria for
typical KD on admission. They were treated with oral
aspirin and 1 or 2 g/kg of IVIG, the latter of which was
administered over 12 or 24 hours, respectively. The IVIG
products were freeze-dried sulfonated (Kenketsu Veni-
lon
®-I, Chemo-Sero-Therapeutic Research Institute,
Kumamoto, Japan) and freeze-dried, polyethylene glycol
(PEG) -treated (Kenketsu Glovenin
®-I, Nihon Pharma-
ceutical Co, Ltd, Tokyo, Japan) human normal immuno-
globulin. Testing of the CSF was done soon after the
diagnosis of suspected IVIG-induced meningitis, and a
diagnosis of meningitis was made on the basis of clinical
symptoms such as fever and headache, meningeal irrita-
tion signs, and CSF pleocytosis. A final diagnosis of asep-
tic meningitis was made by negative bacterial culture
results.
Results
Characteristics of the study population and IVIG products
A total of 384 patients with KD were admitted to our hos-
pital; 4 developed aseptic meningitis after IVIG. Table 1
shows the background characteristics of these 4 patients.
Three were females older than 5 years. The other patient
was a 1-year-old male. Their serum C-reactive protein
(CRP) levels and white blood cell counts before IVIG
treatment were 3.3-5.5 mg/dL and 6,500-27,100/μL,
respectively. Sulfonated immunoglobulin was given to 2
patients, and a polyethylene glycol-treated product was
given to the other 2 patients. Two patients were treated
with 1 g/kg IVIG, and the other 2 received 2 g/kg IVIG.
There were no adverse reactions during the IVIG adminis-
tration in any of the patients.
Clinical course and laboratory findings
All 4 patients responded well to initial IVIG: their fevers
ceased and the clinical symptoms of KD improved.
Table 2 shows the clinical course of the patients. Asep-
tic meningitis developed within 48 hours (range, 25-40
hours) after initiation of IVIG. All 4 patients developed
a sudden, severe fever. Their recorded highest body
temperatures were 38.0, 38.7, 38.8, and 39.1°C. The 3
females complained of headache, and the 1-year-old
male was irritable and vomited frequently. On physical
examination, there were typical signs of meningeal irri-
tation, including neck rigidity, Kernig’ss i g n ,a n dB r u d -
zinski’s sign. Table 3 shows the CSF findings of the 4
patients. The initial pressure was recorded in 1 patient
and was mildly elevated (24 cm H2O). The analyses of
the CSF revealed elevated white blood cell counts
(22-1,248/μL) in all 4 patients, 3 of whom were neutro-
phil-predominant (65%-89%). The CSF protein level was
elevated in only 1 patient (59 mg/dL), and the glucose
levels were normal in all 4 patients (51-77 mg/dL). The
CSF chloride and lactate dehydrogenase (LDH) levels
were measured in 3 patients and were normal (123-128
mEq/L and 33-40 U/L, respectively). In addition, the
results of CSF bacterial culture were negative in all
patients. There was no worsening of inflammatory mar-
kers, ie, serum CRP and peripheral white blood cell
counts, at the onset of meningitis (mean ± SD CRP:
4.3 ± 4.1 mg/dL, WBC: 9,300 ± 7,700/μL), as compared
with the levels at admission (mean ± SD CRP: 5.9 ±
2.0 mg/dL, WBC: 14,800 ± 9,000/μL). Two patients
were treated with a single dose of 15 mg/kg of intrave-
nous methylprednisolone; the other 2 patients recovered
without medical treatment. Fever and signs of meningeal
irritation disappeared in 1 or 2 days, and no patient
developed any neurological complications such as sei-
zures or disturbances in consciousness. There was no
recurrence of KD in any of the patients, and all four
patients were discharged without coronary artery
aneurysms.
Discussion
Aseptic meningitis after IVIG was first reported in 1988
[6]. Since then, there have been similar case reports of
IVIG-induced meningitis in patients with medical condi-
tions such as idiopathic thrombocytopenic purpura
Table 1 Background characteristics of the patients
Age Sex KD criteria CRP(mg/dL)/WBC(/μL)
on admission
IVIG product and dose Day on IVIG
1 y male 5/6 5.5/6,500 PEG-treated
2 g/kg
8
6 y female 5/6 7.1/15,600 Sulfonated
1 g/kg
5
7 y female 6/6 7.8/27,100 Sulfonated
2 g/kg
5
10 y female 6/6 3.3/9,900 PEG-treated
1 g/kg
4
KD = Kawasaki disease; CRP = C-reactive protein; WBC = white blood cell; IVIG = intravenous immunoglobulin; PEG = polyethylene glycol.
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ing neuropathy [7-9]. There has previously been only 1
case report describing this complication in a patient
with KD [10].
The rate of aseptic meningitis after IVIG was 1% (4 of
384) in this study, but the frequency varies widely, from
0% to 11%, in reports of patients with different underly-
ing diseases [11,12]. It was also reported that the devel-
opment of aseptic meningitis was not correlated with
the patient age or the type of underlying neuromuscular
disease [12].
Hamrock reported that most patients who developed
aseptic meningitis received 2 g/kg of IVIG, and that
meningitis did not occur in any of their patients receiving
a standard replacement dose of IVIG for a congenital
immunodeficiency [5]. All of our patients received high-
dose IVIG at a dose of 1 or 2 g/kg. Our patients almost
equally received sulfonated IVIG or PEG-treated IVIG,
and 2 patients in each group (total 4) developed meningi-
tis, thus indicating that there are no apparent differences
in the effects of sulfaonated or PEG-treated IVIG with
regard to the development of meningitis. In this study,
patients were exposed to either sulfonated IVIG or PEG-
treated IVIG, but not to products manufactured by other
processes such as cold ethanol Cohn fractionation/ultrafil-
tration, ion exchange, or low-PH treatment. The inability
to further explore the possible etiological factors related to
specific IVIG brand or manufacturing lots may be a limita-
tion of this study. There were no obvious differences of
clinical and laboratory data, including the severity of KD
on admission, day of initiating IVIG, or changes of inflam-
matory markers after IVIG between patients who devel-
oped meningitis and those who did not.
In the present study, aseptic meningitis developed
within 25 to 40 hours after initiation of IVIG. In pre-
vious case reports, most patients also developed menin-
gitis within 48 hours of beginning IVIG. Although all of
our patients developed a fever and typical meningeal
irritation signs, it may be possible that milder cases of
aseptic meningitis could be misdiagnosed as IVIG-
refractory KD, since the onset of fever after completion
of IVIG therapy is often interpreted as recrudescence of
KD. It is important to consider the possibility of IVIG-
induced meningitis with careful physical examinations
to avoid unnecessary therapies, such as additional IVIG,
steroids, and infliximab.
CSF examinations revealed neutrophilic pleocytosis in
3 of our 4 patients, slight elevation of the protein level in
1 patient, and normal glucose levels in all 4 patients.
These findings were similar to those of previous reports.
The analysis of the CSF in patients with aseptic meningi-
tis usually shows pleocytosis with neutrophil predomi-
nance, normal or slightly elevated protein, and normal
glucose levels. It may therefore be difficult to differentiate
IVIG-induced meningitis from viral meningitis by the
CSF findings, as it has been reported that the CSF protein
levels are normal to mildly elevated, glucose levels are
normal to slightly depressed, and neutrophil predomi-
nance is also seen in pediatric patients with viral menin-
gitis [13,14].
All of our patients recovered without developing any
neurological complications. Two were treated with
intravenous methylprednisolone, and the other 2 were
monitored without medical treatment. Jayabose et al.
reported that children with ITP who were given predni-
sone had a lower risk of neurological complications
after IVIG [15]. However, it has also been reported that
such symptoms are self-limiting, and that there is no
specific therapy that shortens the duration of symptoms.
Thus, it may be advisable to carefully observe such
patients and avoid systemic therapy [5]. In our study,
there were no obvious differences in the clinical courses
between patients treated with intravenous methylpredni-
solone and those who received no medical treatment,
Table 2 The clinical course of the patients
Patient Time from start of IVIG to onset, hrs Treatment Time to recovery
1 y male 33 15 mg/kg mPSL 1 day
6 y female 40 15 mg/kg mPSL 2 days
7 y female 25 None 2 days
10 y female 31 None 1 day
IVIG = intravenous immunoglobulin; mPSL = methylprednisolone.
Table 3 Cerebrospinal fluid findings
Patient Cells (/μL) Glucose (mg/dL) Protein (mg/dL) LDH (U/L)
1 y male 1,248 (P 89%) 51 59 39
6 y female 120 (P 13%) 54 23 33
7 y female 648 (P 83%) 77 30 40
10 y female 21 (P 65%) 52 37 NT
LDH = lactate dehydrogenase; P = polynuclear cells; NT = Not tested.
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not beneficial for IVIG-induced meningitis.
The mechanisms underlying IVIG-induced meningitis
are not clear. One possible cause is an allergic hypersensi-
tivity reaction caused by direct entry of the IVIG prepara-
tion into the CSF compartment. This is supported by the
fact that CSF eosinophilia has been observed in some
patients [11]. In our study, one patient exhibited periph-
eral eosinophilia (11% of the total 5,800/μL white blood
cells) but CSF eosinophilia was not observed in any of our
patients. None of our patients developed exanthema after
IVIG. Although our patients received no pre-treatment, it
may be useful to give antihistamines prior to IVIG if aller-
gic reaction is one of the mechanisms responsible for
IVIG-induced meningitis. Recently, it was reported that
there were increased levels of CSF monocyte chemoattrac-
tant protein-1 (MCP-1) in ITP patients with IVIG-induced
meningitis, which suggests a role for monocytes in the
inflammation of the meninges [16]. On the other hand,
Jarius et al. reported that aseptic meningitis was frequently
associated with neutrophillic pleocytosis in the CSF and in
vivo activation of TNF-a-primed neutrophils by atypical
antineutrophil cytoplasmic antibodies in IVIG might con-
tribute to aseptic meningitis [17]. In our present study, the
CSF cytokines or chemokines were not measured.
Meningitis is also a known complication of KD. Dengler
et al reported that one-third of patients with KD who
underwent a lumbar puncture had CSF pleocytosis with
mononuclear cell predominance [18], which is in contrast
to the polynuclear cell predominance observed in IVIG-
induced meningitis. Meningitis as a complication of KD
usually occurs early in the co u r s eo ft h ed i s e a s ea n d
improves after KD treatment, which is mainly IVIG therapy
[19]. Table 4 shows a comparison between IVIG- and KD-
induced meningitis. It is not difficult to differentiate IVIG-
induced meningitis from aseptic meningitis complicating
KD, as both the time of onset and CSF findings differ.
Conclusions
In conclusion, IVIG-induced meningitis developed
within 48 hours of initiating IVIG and resolved in a few
days, without neurological complications, and systemic
steroid administration was not beneficial in our patients.
Further investigations of the pathophysiology of IVIG-
induced meningitis, including a detailed analysis of the
underlying mechanisms, are needed.
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